BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

Clinical trials for BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA explained in plain language.

Never miss a new study

Get alerted when new BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA trials appear

Sign up with your email to follow new studies for BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New combo pill aims for deep remission in blood cancer, hoping patients can stop treatment

Disease control Recruiting now

This study is testing whether adding a pill called ASTX727 to the standard drug dasatinib works better for people newly diagnosed with a slow-growing type of blood cancer called chronic myeloid leukemia (CML). The goal is to achieve a very deep remission, where the cancer is near…

Matched conditions: BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 18, 2026 14:40 UTC

BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

Get alerted when new BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA trials appear

New combo pill aims for deep remission in blood cancer, hoping patients can stop treatment